Improving GS-CHO Cell Line Selection: Reducing Time to Clinic
|
|
- Lenard Freeman
- 7 years ago
- Views:
Transcription
1 Cell Line Development and Engineering 2-6 March 2009, Berlin Improving GS-CHO Cell Line Selection: Reducing Time to Clinic Adrian Haines, 2009 Lonza Biologics plc, Slough, UK
2 Disclaimer Certain matters discussed in this presentation may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, Lonza Group Ltd has no obligation to update the statements contained in this presentation. Note: All slides are incomplete without verbal comments. slide 2
3 Overview Historical view of cell line constructions: Traditional 95 week process (what processes looked like 10+ years ago) Classic 40 week process Developing a shorter process: Rapid 23 week process Considerations in developing a 23 week process How faster processes fit with cgmp material supply Summary slide 3
4 Considerations for cgmp Cell Line Development High productivity >2 g/l monoclonal antibody Product characteristics e.g. glycosylation, de-amidation, aggregates, bioactivity, other PTMs Clonality demonstrate monoclonality e.g. formal cloning round(s) No animal components e.g. chemically defined, animal component free Scaleability consistent growth and productivity as scale increases Stability consistent expression and product characteristics SPEED fast cell line construction slide 4
5 High Productivity But Rapidly! Use of platform process Media, feeds, fermentation conditions, purification (especially for antibodies) Rapid generation of cell lines Cell line creation is on critical path Carry out as rapidly as possible without compromising productivity, clonality or product characteristics Predictive scale-up systems slide 5
6 Manufacture of a Therapeutic Protein: The Process from Cell to Clinic Cell Line Construction cgmp Cell banking Process development Scale-up & pilot prodn. cgmp manufacture slide 6
7 Historical 95 Week Cell Line Construction Process Total Process Transfection & selection Amplification & selection (1 round) Suspension evaluation (low serum) Limiting diln. cloning (2 rounds) Suspension evaluation (serum-free) Select lead cell lines Weeks slide 7
8 Key Contributors to Historical 95 Week Timeline Gene amplification (~10 weeks per round) Adaptation of cells (CHO) to single cell suspension culture in serum-free medium (~ 30 weeks) Cloning (~ 20 weeks for 2 rounds of limiting dilution cloning) slide 8
9 How have Timelines for Cell Line Development been Reduced? Avoid amplification Use of single cell suspension adapted host cells Avoid multiple cloning steps Direct cloning from transfectant pools Screening process which is relevant to platform production process slide 9
10 Avoid Amplification Choice of expression technology the GS System Highly stringent selection Use weak promoter on GS gene selects for integration into highly transcriptionally active sites in genome increase stringency of selection by use of GS inhibitor methionine sulphoximine (MSX) Linked product gene driven by strong promoter (hcmv) to give high expression Time saving ~ 10 weeks per round of amplification omitted slide 10
11 Number of Cell Lines Product Concentration Distribution from Cell Lines Grown in Fed-Batch Shake-Flasks 175 cell lines were isolated without screening from a single cell line construction assessed in fed-batch shake-flask Product Concentration (mg/l) slide 11
12 How can Timelines for Cell Line Creation be Reduced? Avoid amplification Use of single cell suspension adapted host cells Time saving ~ 30 weeks Avoid multiple cloning steps Direct cloning from transfectant pools Screening process which is relevant to platform production process slide 12
13 Contribution of CHOK1SV Cell Line CHOK1SV is a variant of CHOK1 Grows spontaneously in single cell suspension culture in protein free, chemically defined medium, free of animal derived components Improved growth characteristics compared with parent line - benefits productivity Fast suspension re-adaptation after transfection/cloning Switch very quickly between static and suspension culture slide 13
14 Comparison: CHOK1 vs. CHOK1SV cell lines Viable cell concentration (10 6 /ml) Time (h) LB01 22H11 Host cell line IVC 10 6 cells /ml.h Qp pg/cell.h mab mg/l CHOK1SV CHO-K GS cell lines making the same recombinant antibody Chemically defined protein free medium Fed-batch culture slide 14
15 How can Timelines for Cell Line Creation be Reduced? Avoid amplification Use of single cell suspension adapted host cells Avoid multiple cloning steps Direct cloning from transfectant pools Screening process which is relevant to platform production process slide 15
16 Avoiding Multiple Cloning Steps Traditional: limiting dilution methods takes ~ 20 weeks for 2 rounds Classic: use of Capillary Aided Cell Cloning Direct visualisation to confirm monoclonality Saves 10 weeks With other improvements resulted in cell line creation from transfection to lead candidates in ~ 40 weeks slide 16
17 Clonal GS-CHO Cell Lines: Classic Two Step Process 40 Weeks from Transfection to Lead Cell Lines Transfer high-ranked cell lines Transfect CHOK1SV host cells with vector Bioreactor studies etc. cells in 96-well plates Week 40: choose lead cell lines capillary aided cell cloning cells Static in 24-well flasks plates High-ranked cell lines progressed GMP cell banking Stability study Screen and grow cells in shaking flasks: evaluate productivity and growth characteristics for manufacturability slide 17
18 Number of Cell Lines (Each Making a Different Product) Antibody Concentrations from GS-CHO Cell Lines >4 Product Concentration (g/l) cgmp manufacturing bioreactors at scale (200 to L) Harvested no later than 15 days after inoculation slide 18
19 Improved Cell Line Construction Process Total CLC Transfection & selection Amplification & selection (1 round) Suspension evaluation (low serum) Limiting diln. cloning (2 rounds) Suspension evaluation (serum-free) Select lead cell lines Total CLC Transfection & selection Suspension evaluation (protein-free) Capillary-aided cell cloning (1 round) Suspension evaluation (protein-free) Select lead cell lines Traditional: 95 week process Classic: 40 week process Weeks slide 19
20 How can Timelines for Cell Line Creation be Reduced Further? Avoid amplification Use of suspension adapted host cells Avoid multiple cloning steps Direct cloning from transfectant pools slide 20
21 Direct Cloning From Transfectant Pools Collapse two rounds of screening to one round Transfectant pools are mixtures of high and low producing cell lines Manual capilliary aided cell cloning, without identifying high expressors, not suitable as number of clones to be screened is substantially higher Can use methods such as antibody capture and flow cytometry analysis to identify putative high producers at the point of cloning, but technically complex often with poor robustness frequently requires animal derived materials Automated single cell cloning by use of cell sorter without identifying high producers is suitable slide 21
22 Clonal GS-CHO Cell Lines: Rapid One Step Process 23 Weeks from Transfection to Lead Cell Lines Generate pools of transfectants Automated cloning Identify monoclonal cell lines Productivity assessment Transfer highranked cell lines Cell sorter Automated imaging Transfect CHOK1SV host cells with vector Productivity assessment Week 23: choose lead cell lines High-ranked cell lines progressed Bioreactor studies, etc. High ranked cell lines progressed GMP cell banking Stability study Fed-batch assessment CSI of automated growth, productivity imaging platform and product quality Productivity assessment 5 10 cell lines (abridged fed-batch) slide 22
23 Considerations Pool generation and selection Pools contain cells with a range of expression levels Generate a variety of pools and pre-screen for expression to identify the best pools Is the proportion of non- or low expressing cell lines derived from sorting a transfectant pool greater than when derived by a classic method? Verification likelihood of monoclonality slide 23
24 Proportion of non or low expressing cell lines: Classic v sorting from pool Classic: Productivity assessment Transfect CHOK1SV host cells with vector Sorting: Generate pools of transfectants Automated cloning Cell sorter Productivity assessment Transfect CHOK1SV host cells with vector slide 24
25 Proportion of non- or low expressing cell lines: Classic v sorting from pool Classic: 208 colonies were recovered after transfection Colonies were assessed for secreted production of antibody in static multi-well plates (un-fed culture) mean productivity = 40 mg/l proportion producing less than 25 mg/l = 46% Sorting: 275 colonies were recovered after cell sorting 156 colonies were assessed for production of antibody in static multi-well plates (un-fed culture) mean productivity = 91 mg/l proportion producing less than 25 mg/l = 5% slide 25
26 Proportion of cell lines (%) Productivity distribution of colonies: Classic v sorting from pool > 200 Productivity distribution (mg/l) Classic (n=208) Sorting (n=156) slide 26
27 Summary of cell growth and productivity: Classic v sorting from pool Method used No. of multiwell plates No. of colonies recovered Colonies per plate No. of colonies screened Antibody product conc. Classic Sorting Cloning from transfectant pools without screening at the cloning stage for higher producers, does not result in an increased proportion of non- or low expressers slide 27
28 Considerations Pool generation and selection Pools contain cells with a range of expression levels Generate a variety of pools and pre-screen for expression to identify the best pools Is the proportion of non- or low expressing cell lines derived from sorting a transfectant pool greater than when derived by a classic method? Verification likelihood of monoclonality slide 28
29 Sorting: Verify Likelihood of Monoclonality Three arms to verify the likelihood of monoclonality: Correct instrument set-up and operational checks Historical data set and statistical model for analysing data Visual monitoring of plating, pre- and post-sort slide 29
30 Sorting: Why do we Need to Assess Clonality? Surely a fluorescent activated cell sorter operating in single cell mode will only deposit a single cell per well? slide 30
31 Sorting: Historical Data Analysis Sorted cells into well plates 5982 wells were analysed for presence or absence of cells 1626 wells were empty (no cells) 4330 wells contained one cell 26 wells contained 2 or more cells Overall population containing 2 or more cells = 0.43% Probability that a well contains 1 particle = 0.72 If sort into well plates 240 x 96 x 0.43% = >1 cell / well Need to ensure optimal set up slide 31
32 Sorting: Optimal Set Up At each sort session: Check single particle deposition on subset of plates - visual inspection of one particle per well Perform the sort Repeat single particle deposition on subset of plates - visual inspection of one particle per well Statistical analysis slide 32
33 Data Analysis Historical data Data obtained from pre + post sort checks on single cell deposition Calculated probability for the sort Start, p(x=0) probability of 0 cells/well Start, p(x=1) probability of 1 cell/well Bayes theorem used to combine historical data on single particle deposition (prior) and data from the experiment itself (likelihood) to estimate probabilities that wells contain different numbers of particles (posterior) slide 33
34 P(monoclonality P(monoclonality) Once have probabilities for a well containing n cells, can calculate p(monoclonality) Using probabilities from start and end of session, can estimate range of likely values for p(monoclonality) Session slide 34
35 Sorting: Further Assurance of Clonality Screen and select colonies using a Clone Select Imager Automated imaging of 96-well plates Identifies single colonies Repeat imaging allows colony growth to be tracked slide 35
36 Assurance of monoclonality 3 orthogonal approaches: Use of cell sorter Confirmation of correct instrument function Pre- and post-sort checks Statistical analysis Use of image analysis to track colony formation slide 36
37 Effect of Shortening CLC: Typical Examples DNA Sequence to Clinical supply Traditional 95 week CLC GMP material Classic two step (Capillary aided cell cloning) 40 week CLC GMP material 35 weeks Rapid one step (Cell Sorting) 23 week CLC GMP material Months DNA seq. optimization and prep. Cell line stability studies MCB Process development and pilot cgmp manufacture slide 37
38 Summary 1 Traditional 95 week process can be shortened to 40 weeks by Removing amplification stages Avoiding adapting cells to suspension culture in chemically defined medium by using a suspension variant (e.g.chok1sv) Using one round of cloning, such as capillary aided cloning Process can be further shortened to 23 weeks by cloning directly from transfected pools using a cell sorter Eliminates a round of screening No increase in proportion of low or non-expressers compared to classic method Demonstrate likelihood of monoclonality slide 38
39 Summary 2 Reduce historical timeline of >18 months to < 6 months (from transfection to selection of clonally derived lead candidates) GMP material can be prepared within ~14 months from DNA sequence slide 39
40 Acknowledgments Andy Racher Hilary Metcalfe James Rance Tabitha Bullock Frances Kenny Kasia Szymaniec Deepa Pillai Marc Smith Matthieu Stettler Sarah Turner Alison Porter John Birch Other members of CCPD past and present Analytical Development Dept. slide 40
Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development
Pharma&Biotech Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development James Rance PhD Head of Development Services Singapore Lonza Biologics
More informationThe Importance of Developing a High Yield of Product
European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc Monoclonal Antibodies A Success Story Fastest growing segment of
More informationESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES. Dr Andrew Racher
ESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES Dr Andrew Racher Lonza Biologics plc, 2004 Structure of talk Issues Selection of a high producing cell line Selection for process compatibility
More informationSelection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting. Andrew Racher Lonza Biologics
Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting Andrew Racher Lonza Biologics Structure of Talk 1. The Problem 2. Possible Solutions 3. Solution Chosen
More informationPotelligent CHOK1SV. European Antibody Congress 30 Nov - 02 Dec, Geneva, Switzerland. Alison Porter, 2009 Lonza Biologics plc, Slough, UK
Potelligent European Antibody Congress 30 Nov - 02 Dec, Geneva, Switzerland Alison Porter, 2009 Lonza Biologics plc, Slough, UK Disclaimer Certain matters discussed in this presentation may constitute
More informationHow To Develop A Cell Line
Advances in The Development of Biopharmaceuticals The application of modern technologies and services to the development of Biopharmaceutical processes Dr Jonathan H Dempsey Process Science Fellow Invitrogen
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationA customizable ADCC assay service for antibodies & fusion proteins.
Antibody Dependent Cell- Mediated Cytotoxicity (ADCC) Assay A customizable ADCC assay service for antibodies & fusion proteins. Our ADCC assay service accurately detects cell lysis based on LDH-release.
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationThe use of FACS for the selection of cell lines with superior productivity characteristics
ESACT-UK, Cambridge 2007 The use of FACS for the selection of cell lines with superior productivity characteristics Jonathan Welsh Synopsis Why use FACS in bioprocess development Issues regarding use of
More informationEMABling Antibody Production Platform
EMABling Antibody Production Platform An industrial solution for the production of therapeutic antibodies with high cytotoxic activity B IOMANUFACTURING EMABling : A fully integrated development platform
More informationImportant Topics in the Expression of Recombinant Antibodies from CHO Cells
Cell Line Development and Engineering Workshop, Prague, March 2008 Important Topics in the Expression of Recombinant Antibodies from CHO Cells Robert Young/Lonza Biologics/Mar 2008 Disclaimer Certain matters
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationHigh yield antibody production in a disposable WAVE Bioreactor
High yield antibody production in a Process intensification using perfusion culture Christian Kaisermayer 1, Jianjun Yang 2 1 GE Healthcare Europe GmbH, Vienna, Austria (Christian.Kaisermayer@ge.com),
More informationBaculoDirect Baculovirus Expression System Free your hands with the BaculoDirect Baculovirus Expression System
BaculoDirect Baculovirus Expression System Free your hands with the BaculoDirect Baculovirus Expression System The BaculoDirect Baculovirus Expression System gives you: Unique speed and simplicity High-throughput
More informationTechnologies for Monoclonal Antibody Production
Technologies for Monoclonal Antibody Production First we help you bridge the distance between upstream and downstream. Then we help you shorten it. Monoclonal antibodies for therapeutic, diagnostic and
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationDescription: Molecular Biology Services and DNA Sequencing
Description: Molecular Biology s and DNA Sequencing DNA Sequencing s Single Pass Sequencing Sequence data only, for plasmids or PCR products Plasmid DNA or PCR products Plasmid DNA: 20 100 ng/μl PCR Product:
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationEuropean Medicines Agency
European Medicines Agency July 1996 CPMP/ICH/139/95 ICH Topic Q 5 B Quality of Biotechnological Products: Analysis of the Expression Construct in Cell Lines Used for Production of r-dna Derived Protein
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE QUALITY OF BIOTECHNOLOGICAL PRODUCTS: ANALYSIS
More informationCatalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
More informationTransIT -2020 Transfection Reagent
Quick Reference Protocol, MSDS and Certificate of Analysis available at mirusbio.com/5400 INTRODUCTION TransIT -2020 Transfection Reagent is a high-performance, animal-origin free, broad spectrum reagent
More informationMAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project
Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production
More informationGenes to Proteins to Antibodies
Genes to Proteins to Antibodies About Us Fusion Antibodies is a CRO established in 2001 as a spin-out from Queen s University Belfast. The company building is situated in a charming area of Springbank
More informationSecretion Assay Cell Screening Service Gel Microdrop
Cell Screening Service Gel Microdrop The Cell Screening Service is comprised of five phases: 1) Evaluation of the Cell Line after encapsulation; 2) Assessment of Reagents; 3) Secretion Assay Optimization;
More informationUse of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development
Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development Authors: Dr Fern Slingsby and Dr Simon Dewar Upstream Process Development FUJIFILM
More informationFrom cells to therapeuticsvivalis. Humalex Fully human antibody discovery platform An integrated therapeutic development offering
From cells to therapeuticsvivalis Humalex Fully human antibody discovery platform An integrated therapeutic development offering Humalex from bench-top to clinical development The Humalex platform enables
More informationEden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
More information3 Chapter Three: Material and methods (clone creation, upstream and downstream process)
3 Chapter Three: Material and methods (clone creation, upstream and downstream process) 3.1 Model proteins and CHO cell cultures Two recombinant produced, CHO-cell-derived model-glycoproteins, a less glycosylated
More informationMonoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationMolecular Biology Techniques: A Classroom Laboratory Manual THIRD EDITION
Molecular Biology Techniques: A Classroom Laboratory Manual THIRD EDITION Susan Carson Heather B. Miller D.Scott Witherow ELSEVIER AMSTERDAM BOSTON HEIDELBERG LONDON NEW YORK OXFORD PARIS SAN DIEGO SAN
More informationBioProcessing J O U R N A L. Trends and Developments in BioProcess Technology. Volume 9 Issue 1 ISSN 1538-8786
A Production of ISBioTech Summer 2010 Issue BioProcessing J O U R N A L Trends and Developments in BioProcess Technology Volume 9 Issue 1 ISSN 1538-8786 Trends & Developments in BioProcess Technology Novel
More informationChapter 18: Applications of Immunology
Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing
More informationFacility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study
24 th Interphex, Japan, Technical Conference June 29 th, 2011 Michael Brown Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study Lonza AG Financially
More informationDr.ssa Maria Luisa Nolli CEO
IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationIntegrated Protein Services
Integrated Protein Services Custom protein expression & purification Version DC04-0012 Expression strategy The first step in the recombinant protein generation process is to design an appropriate expression
More informationAviva Systems Biology
Aviva Custom Antibody Service and Price Mouse Monoclonal Antibody Service Package Number Description Package Contents Time Price Customer provides antigen protein $6,174 Monoclonal package1 (From protein
More informationCustom Antibody Services
Custom Antibody Services Custom service offerings DNA sequence Plasmid Peptide Structure Protein Peptide Small molecule Cells Spleen Lymphocytes Antigen Preparation Immunization Fusion & Subcloning Expansion
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationPX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
More informationAnalyzing antibody sequence for recombinant antibody expression. Hangxing Yu, Ph.D Senior Scientist, GenScript May 20, 2015
Analyzing antibody sequence for recombinant antibody expression Hangxing Yu, Ph.D Senior Scientist, GenScript May 20, 2015 Presentation Outline 1 2 3 4 Antibody basics, structure and function Antibody
More informationTHE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS
THE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS Table of Contents CHAPTER 1: Overview of Monoclonal Antibody Therapeutics CHAPTER 2: Monoclonal Antibody Discovery Technologies CHAPTER 3: CMC
More informationPRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY
PRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY Guideline Title Production and Quality Control of Medicinal Products derived by recombinant DNA Technology Legislative
More informationApplication Note. Separation of three monoclonal antibody variants using MCSGP. Summary
Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal
More informationHuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial
More informationProviding Trusted and Innovative Solutions t o the Life Science Communities
Providing Trusted and Innovative Solutions t o the Life Science Communities Eurogentec Eurogentec is a leading supplier of trusted and innovative reagents, kits, specialty products and custom research/development
More informationIntegrated Protein Services
Integrated Protein Services Custom protein expression & purification Last date of revision June 2015 Version DC04-0013 www.iba-lifesciences.com Expression strategy The first step in the recombinant protein
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationCell Discovery 360: Explore more possibilities.
Cell Discovery 360: Explore more possibilities. Flexible solutions for the BioPharma laboratory Blood Banking Capillary Electrophoresis Centrifugation Flow Cytometry Genomics Lab Automation Lab Tools Particle
More informationMGC premier Expression-Ready cdna clones TCH1103, TCM1104, TCR1105, TCB1106, TCH1203, TCM1204, TCR1205, TCB1206, TCH1303, TCM1304, TCR1305
MGC premier Expression-Ready cdna clones TCH1103, TCM1104, TCR1105, TCB1106, TCH1203, TCM1204, TCR1205, TCB1206, TCH1303, TCM1304, TCR1305 The MGC premier Expression-Ready collection has the high quality,
More information"Small and large molecules bioproduction by mammalian and microbial fermentation"
"Small and large molecules bioproduction by mammalian and microbial fermentation" H.-P. Meyer Bio/PharMOS 2004-23-25 March 2004 Symposium B Business Diversification in Life Science "Small and large molecules
More informationAnimal Cell Culture. Third Edition. A Practical Approach OXJORD VNIVVRSITY 1'RVSS
Animal Cell Culture Third Edition A Practical Approach Edited by John R. W. Masters 3rd Floor Research Laboratories, University College London OXJORD VNIVVRSITY 1'RVSS Contents List of protocols page xiii
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationCell Culture Technology for Pharmaceutical and Cellular Therapies
Cell Culture Technology for Pharmaceutical and Cellular Therapies Sadettin S. Ozturk, Ph.D. Centocor Inc. 200 Great Valley Parkway, Malvern, PA 19355 Outline 1. Introduction to Monoclonal Antibodies 2.
More informationAviva Systems Biology
Aviva Custom Antibody Services and Prices Rabbit Polyclonal Antibody Service Package Number Description Package Contents Time Price Polyclonal package 1 (From protein to antiserum) Polyclonal package 2
More informationAntibody Production Price List
Antibody Production Price List Presenting Insight Biotechnology s price list for custom polyclonal and monoclonal antibody production services. We are happy to tailor individual packages towards the specific
More informationAccelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches
Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches 2008 IBC Formulation Strategies for Protein Therapeutics Tim Kelly, Ph.D.
More informationBioprocessing Media and Buffers Grow with Us
Bioprocessing Media and Buffers Grow with Us Experience Highly experienced media on the selection of standard media as well as development This service packaging, documentation Leading position in single-use
More informationContinuous Chromatography for Monoclonal Antibody Purification from Cell Culture Supernatant
Continuous Chromatography for Monoclonal Antibody Purification from Cell Culture Supernatant Massimo Morbidelli Institute for Chemical and Bioengineering, ETH Zurich, Switzerland www.morbidelli.ethz.ch
More informationProcess Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
More information3rd Annual Modern Challenges in Therapeutic Protein Production Event The Penridge Suite, London, N11 1NL, UK : Thursday, 14 June 2012
3rd Annual Modern Challenges in Therapeutic Protein Production Event The Penridge Suite, London, N11 1NL, UK : Thursday, 14 June 2012 The purpose of this annual event is to look at the challenges facing
More informationAdvances inthe Development. of Therapeutic
Advances inthe Development of Therapeutic Monoclonal Antibodies Susan Dana Jones, Francisco J. Castillo, Howard L. Levine ABSTRACT Monoclonal antibodies (MAbs) and related products are a dominant component
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationEspecially developed for the transfection of mammalian cells with sirna or mirna
METAFECTENE SI Especially developed for the transfection of mammalian cells with sirna or mirna For ordering information, MSDS, publications and application notes see www.biontex.com Description Cat. No.
More informationSCANTIBODIES Laboratory, Inc. Contract Monoclonal Antibody Production
A Technical Publication of SCANTIBODIES Laboratory, Inc. Volume 1 Number 4 9336 Abraham Way Santee, CA 92071 USA (619) 258-9300 fax (619) 258-9366 www.scantibodies.com SCANTIBODIES Laboratory, Inc. Contract
More informationAdvances in Biopharmaceutical and Vaccine Manufacturing Plants
Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative
More informationRisk-Based Change Management Using QbD Principles
Risk-Based Change Management Using QbD Principles Lynne Krummen, Ph.D. VP, Global Head, Technical Regulatory Biologics Genentech, a member of the Roche Group CMC Forum 2013 Tokyo, Japan Presentation Outline
More informationApplication Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary
Application Note Purifying common light-chain bispecific antibodies using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, biochromatography Antibodies MCSGP Bispecific antibody,
More informationYour partner in immunology
Your partner in immunology Expertise Expertise Reactivity Reactivity Quality Quality Advice Advice Who are we? Specialist of antibody engineering Covalab is a French biotechnology company, specialised
More informationAbout Our Products. Blood Products. Purified Infectious/Inactivated Agents. Native & Recombinant Viral Proteins. DNA Controls and Primers for PCR
About Our Products Purified Infectious/Inactivated Agents ABI produces a variety of specialized reagents, allowing researchers to choose the best preparations for their studies. Available reagents include
More informationHuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody
More informationApplication Note USD3013. Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor
Application Note USD313 Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor Introduction Single use solutions are found in many applications as they offer
More informationMGC premier full length cdna and ORF clones
MGC premier full length cdna and ORF clones TCH1003, TCM1004, TCR1005, TCB1006, TCL1007, TCT1008, TCZ1009, TOH6003, TOM6004, TOZ6009, TCHS1003, TCMS1004, TCRS1005, TCBS1006, TCLS1007, TCTS1008 MGC premier
More informationLecture 13: DNA Technology. DNA Sequencing. DNA Sequencing Genetic Markers - RFLPs polymerase chain reaction (PCR) products of biotechnology
Lecture 13: DNA Technology DNA Sequencing Genetic Markers - RFLPs polymerase chain reaction (PCR) products of biotechnology DNA Sequencing determine order of nucleotides in a strand of DNA > bases = A,
More informationFast, easy and effective transfection reagent for mammalian cells
METAFECTENE EASY + Fast, easy and effective transfection reagent for mammalian cells For ordering information, MSDS, publications and application notes see www.biontex.com Description Cat. No. Size METAFECTENE
More informationGenetic Engineering and Biotechnology
1 So, what is biotechnology?? The use of living organisms to carry out defined chemical processes for industrial or commercial application. The office of Technology Assessment of the U.S. Congress defines
More informationTransfection reagent for visualizing lipofection with DNA. For ordering information, MSDS, publications and application notes see www.biontex.
METAFECTENE FluoR Transfection reagent for visualizing lipofection with DNA For ordering information, MSDS, publications and application notes see www.biontex.com Description Cat. No. Size METAFECTENE
More informationANTIBODY AND CYTOKINE DEVELOPMENTS AND SERVICES. Zsolt Keresztessy, PhD MBA TUDOMÁNYOS HÉTFŐ 2012.04.23.
ANTIBODY AND CYTOKINE DEVELOPMENTS AND SERVICES AT DEBRECEN CLINICAL GENOMICS CENTER DEPT BIOCHEMISTRY AND MOLECULAR BIOLOGY Zsolt Keresztessy, PhD MBA TUDOMÁNYOS HÉTFŐ 2012.04.23. MISSION CUTTING EDGE
More informationGuideline for Generation of Stable Cell Lines Technical Reference Guide
BioResearch Guideline for Generation of Stable Cell Lines Technical Reference Guide 1. Background Stable, long-term expression of a gene of interest can be either achieved by eukaryotic vectors that harbor
More informationSpecific Challenges in Large-Scale Manufacturing of Peptide as API s Presentation at TIDES Conference, Las Vegas, April 25 29, 2004
Specific Challenges in Large-Scale Manufacturing of Peptide as API s Presentation at TIDES Conference, Las Vegas, April 25 29, 2004 Oleg Werbitzky Slide 2 Agenda Market environment Current manufacturing
More informationOriGene Technologies, Inc. MicroRNA analysis: Detection, Perturbation, and Target Validation
OriGene Technologies, Inc. MicroRNA analysis: Detection, Perturbation, and Target Validation -Optimal strategies to a successful mirna research project Optimal strategies to a successful mirna research
More informationVaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010
Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it
More information50 g 650 L. *Average yields will vary depending upon a number of factors including type of phage, growth conditions used and developmental stage.
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Phage DNA Isolation Kit Product # 46800, 46850 Product Insert
More informationMycoplasma Testing Products & Services. M-175 CELLshipper Mycoplasma Detection Kit (In-house sample preparation and slide fixation)
Cell Culture Testing M-1500 Real-Time PCR with Broth Enrichment A specific and sensitive method for the detection of mycoplasma using Real-Time PCR coupled with a pre-enrichment procedure to enhance method
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationHigh Throughput Robotic Production of Monoclonal Antibodies at MATF. Ed Nice, Daniel Layton, Caroline Laverty, Natasha Dodge,
High Throughput Robotic Production of Monoclonal Antibodies at MATF Ed Nice, Daniel Layton, Caroline Laverty, Natasha Dodge, Bronwyn Briers and Jean Tang Monash Antibody Technology Facility Clayton Victoria
More informationBio-manufacturing of antigens, antibodies and bioresearch materials
Bio-manufacturing of antigens, antibodies and bioresearch materials Foetal Bovine Serum (FBS) Human AB Serum Chick Embryo Extract (CEE) Custom polyclonal antibody production Custom monoclonal antibody
More informationMLX BCG Buccal Cell Genomic DNA Extraction Kit. Performance Characteristics
MLX BCG Buccal Cell Genomic DNA Extraction Kit Performance Characteristics Monolythix, Inc. 4720 Calle Carga Camarillo, CA 93012 Tel: (805) 484-8478 monolythix.com Page 2 of 9 MLX BCG Buccal Cell Genomic
More informationNIH Mammalian Gene Collection (MGC)
USER GUIDE NIH Mammalian Gene Collection (MGC) Catalog number FL1002 Revision date 28 November 2011 Publication Part number 25-0610 MAN0000351 For Research Use Only. Not for diagnostic procedures. ii Table
More information1.Gene Synthesis. 2.Peptide & Phospho-P. Assembly PCR. Design & Synthesis. Advantages. Specifications. Advantages
1.Gene Synthesis Assembly PCR Looking for a cdna for your research but could not fish out the gene through traditional cloning methods or a supplier? Abnova provides a gene synthesis service via assembly
More informationDedicated Project Management
Peptides Dedicated Project Management At Lonza, we are committed to our customers success, so it is our mission to help your product reach its full potential. We pride ourselves on delivering high-quality,
More informationCHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
More informationThe Leading Gene Through Screen CRO
The Leading Gene Through Screen CRO Molecular Biology Services Molecular Biology drives modern drug discovery. Drug screening, target validation and structural biology processes frequently require recombinant
More informationGRS Plasmid Purification Kit Transfection Grade GK73.0002 (2 MaxiPreps)
1 GRS Plasmid Purification Kit Transfection Grade GK73.0002 (2 MaxiPreps) (FOR RESEARCH ONLY) Sample : Expected Yield : Endotoxin: Format : Operation Time : Elution Volume : 50-400 ml of cultured bacterial
More informationExpression and Purification of Recombinant Protein in bacteria and Yeast. Presented By: Puspa pandey, Mohit sachdeva & Ming yu
Expression and Purification of Recombinant Protein in bacteria and Yeast Presented By: Puspa pandey, Mohit sachdeva & Ming yu DNA Vectors Molecular carriers which carry fragments of DNA into host cell.
More information